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An analytical methodology based on cloud point extraction (CPE) coupled to Ultra-Fast Liquid Chro-
matography and electrospray tandem mass spectrometry (UFLC-MS/MS) was developed for analysis of
Abacavir (ABC), Efavirenz (EFV), Lamivudine (3 TC) and Nelﬁnavir (NFV) in human plasma. It is the ﬁrst
time that CPE was used for extraction of antiretrovirals (ARV) from plasma. The effects of relevant physic-
chemical variables on analytical response of each ARV, including pH, surfactant concentration, equili-
bration time and temperature, were study and optimized; as well as its coupling to UFLC-ESI-MS/MS.
Under optimized conditions, the resulting methodology was as follows: a 500 mL aliquot of human
plasma was diluted with 2 mL deionized water in a 10 mL centrifuge tube. A 500 mL aliquot Triton X-114
5% w/v was added and homogenized using a vortex stirrer. The resulting cloudy solution was kept at
65 C for 20 min for promoting the condensation of surfactant micelles. Then it was centrifuged at
3000  g for 5 min for separation of the surfactant-rich phase. After discarding the aqueous supernatant,
400 mL ACN were added to the remaining surfactant rich phase and centrifuged in order to precipitate
proteins and separate them. A 150 mL aliquot of the supernatant was transferred to 2 mL vial and further
diluted with 400 mL deionized water. A 30 mL aliquot of the so-prepared solution was injected and
analyzed into the UFLC-MS/MS. The method detection limits for ABC, EFV, 3 TC and NFV under optimized
conditions were 31, 77, 57 and 21 ng mL1, respectively. The RSD% for the studied analytes were <15%,
except at the LOQ, which were <19%. Recovery values ranged from 81 to 107%. The proposed method-
ology was successfully applied for the analysis of ABC, EFV, 3 TC and NFV in human plasma within the
concentration range of 43e6816, 125e4992, 81e3248 and 49e7904 ng mL1, respectively. Under opti-
mized working conditions the proposed analytical methodology meets standard requirements of inter-
national guidelines, which makes it suitable for pharmacokinetic studies of the four ARV, as well as for
therapeutic monitoring of HIV patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Abacavir (ABC), Efavirenz (EFV), Lamivudine (3 TC) and Nelﬁ-
navir (NFV) are antiretrovirals (ARV) drugs frequently prescribed tombiental, Instituto Argentino
GLA)-CONICET-Mendoza, P.O.
.ar (J.C. Altamirano).
B.V. This is an open access article utreat human immunodeﬁciency virus (HIV) infection [1]. Therapy
based on antiretroviral combination is used for patient treatment
infected with HIV. Accurate dose of ARV is essential in this kind of
therapy for guaranteeing viral suppression, as well as to avoid pa-
tient intoxication [2]. Additionally, reports show that patients
whose therapy is based on dose plasmatic ARV level, responded
better to it than individuals who followed a standard and/or ﬁxed
regimen [3]. Due to the complexity presented by the management
of patients infected with HIV, it seems clear that any way to
monitor the pharmacokinetics of ARV therapy could substantiallynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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drug levels in ARV combination therapy it is important to count on
an analytical methodology for analyzing multi-components in a
single sample. Several methodologies were proposed for the anal-
ysis of ARV in plasma by using modern instrumental technique,
including liquid chromatography coupled to electrospray tandem
mass spectrometry detection (UFLCeMS/MS) [4e6]. As it is well
known, despite the outstanding sensitivity and selectivity of UFLC-
MS/MS, an exhaustive sample preparation is required for an
appropriated multiple ARV analysis; especially when they present
signiﬁcant differences on their physicochemical properties. This
fact, together with the sample volume limitation, the sample
preparation step turns to be a bottle neck for multiple ARV analysis
in biological samples for clinical studies [7].
Several sample preparation techniques have been reported for
extraction and isolation of ARV from plasma before chromato-
graphic analysis. Although the most commonly reported is liquid-
eliquid extraction (LLE) [8,9] and solid phase extraction (SPE)
[10,11]; they have as disadvantages to be laborious, to require a
large sample volume and to be time consuming. An additional
disadvantage of LLE is the use of signiﬁcant amount of volatile and
toxic organic solvents. Moreover, due to the low concentration of
ARV in plasma, large sample volumes are typically required to
ensure their detectability. In recent years, with the developing in-
terest in miniaturization in analytical chemistry for solvent and
sample saving, some newer miniaturized approaches to LLE have
been reported. Several different types of liquid-phase micro-
extraction (LPME) have been developed, including single drop
microextraction (SDME) [12], dispersive liquideliquid micro-
extraction (DLLME) [13] and ultrasound assisted emulsiﬁcation
microextraction (USAEME) [14]. An alternative to the micro-
extraction with traditional organic solvents is the cloud point
extraction technique (CPE) [14,15]. The micelles formation phe-
nomenon is based on the aggregation of surfactants monomers
under speciﬁc physicochemical conditions, which result dispersed
into the sample bulk [16,17]. The resulting micelles provide a new
phasewithin the sample bulk with regions of diverse polarities that
enhance its potential for solubilizing solutes in a wide range of
polarities. The solutes afﬁnity depends on its nature and the sur-
factant structure. Hydrophobic solutes are solubilized in the inner
micellar core, polar/charged analytes are believed to be solubilized
in the polar region through a number of interactions (e.g. electro-
static, p-cation, hydrogen bonds, etc.), and amphiphilic solutes are
incorporated to the micelles through both hydrophobic and polar
interactions, forming mixed aggregates [15,16]. Thus, analytes can
be in-situ extracted into the micellar phase and selectively sepa-
rated from the liquid sample bulk [18]. CPE has been successfully
applied for extraction of a wide range of analytes from biological
[15,19] and environmental media, including estrogens, vitamin A,
vitamin E [16], several kinds of proteins, as well as metal ions
[20,21] prior to liquid chromatography (LC) analysis. In addition to
the analytical advantages, standing out high separation efﬁciency,
selective isolation and wide range of ﬂexibility for coupling it to
different analytical instrumentation [11,21], it is important to
consider the operational advantages. In this sense CPE is low cost,
simple to operate and environmentally friendly because uses
alternative solvents such as surfactants, lowering the organic sol-
vent consumption.
The aim of this work was to develop and validate a methodology
based on CPE coupled to ultra-performance liquid chromatography
and electrospray tandem mass spectrometry detection (UFLC-MS/
MS) for analysis of Abacavir (ABC), Efavirenz (EFV), Lamivudine
(3 TC) and Nelﬁnavir (NFV) in human plasma. Table 1 summarizes
the relevant physicochemical information of the studied ARV of this
work [23]. The effects of relevant physic-chemical variables onanalytical response of each ARV, including pH, surfactant concen-
tration, equilibration time and temperature, were study and opti-
mized; as well as its coupling to UFLC-ESI-MS/MS. The analytical
performance of the proposed method was evaluated in terms of
quantiﬁcation limits (LOQ), repeatability, reproducibility, accuracy,
recovery and linear working range. Moreover, the methodology
was applied for the determination of ABC, EFV, 3 TC and NFV in
human plasma samples of patients under treatment and its
robustness was evaluated in terms of recovery factors (RF%).
2. Experimental
2.1. Chemicals and reagents
Abacavir Sulfate (USP, LOT F1L487, 99.4% w/w), Efavirenz (USP,
LOT F0G376, 99.8% w/w), Lamivudine (USP, LOT H0I378, 99.7% w/
w), Nelﬁnavir Mesylate (USP, LOT F0K050, 98.3% w/w) and
Nelﬁnavir-d3 (Toronto Research Chemicals, LOT 4-SDJ-86-3, 98% w/
w) were supplied by the pharmaceutical industry. Stock solutions
(400 mg mL1 of each ARV) were prepared by dissolving an
appropriate amount of each compound in acetonitrile (ACN).
Working solutions were prepared daily by dilution of the stock
solutions with ACN. Instrument tuning parameters were optimized
using 1000 ng mL1 solutions of each compound prepared in mo-
bile phase (10 mM ammonium acetate:ACN, 70:30 v/v). The Triton
X-114 (AppliChem, Germany) was prepared in deionized water
(DW-conductivity < 3 mS cm1) within the range of 2.5e10% (w/v)
in DW. ACN andmethanol (MeOH)were purchased fromCarlo Erba,
France and Ammonium acetate (NH4Ac) was purchased from Sig-
maeAldrich, Germany. All reagents were analytic grade or above.
2.2. Instrumentation
The assay was carried out by using an ultra-performance chro-
matography coupled to a triple quadrupole (UFLCeMS/MS) in-
strument, described as follows: UFLC Shimadzu (LC 20AD),
automatic injector Shimadzu (SIL-20A XR), coupled to an electro-
spray ionization (ESI) source (Applied Biosystems, Ontario, Can-
ada). Liquid chromatographic analysis was carried out on a Hypersil
Gold C18 column (100 mm  2.1 mm i.d., 3 mm particle, Thermo
Fisher Scientiﬁc, USA). Data were acquired and processed using
Analyst software (version 1.5.1; ABSciex, Toronto, Canada).
2.3. Sampling and sample conditioning
Samples were obtained from volunteers of DominguezLab,
which is developing a program for determining drugs bioequiva-
lence (Protocol number: PRO-BEQ-EFV-001-V.01). Sampling was
carried out using a catheter system (BD Saf-T-Intima™, BD Vacu-
tainer®) and syringes of 5 mL. The blood sample was collected into
heparinized polypropylene 4 mL tubes (NAHEP PLH 13X75 4.0 PLBL
GN, BD Vacutainer®, Broken Bow NE 68822 US) and centrifuged at
3000 rpm (1400  g) for plasma separation. Aliquots of 1 mL were
preserved in polypropylene 2 mL cryovials and frozen
at 20 C ± 5 C until analysis.
2.4. Cloud point extraction
A 500 mL aliquot of human plasmawas diluted with 2 mL DW in
a 10 mL centrifuge tube. An aliquot of 500 mL Triton X-114 5% w/v
was added and homogenized using a vortex stirrer. The resulting
cloudy solution was kept at 65 C for 20 min for promoting the
condensation of surfactant micelles. Then it was centrifuged at
3000 g for 5 min for separation of the surfactant-rich phase. After
discarding the aqueous supernatant, 400 mL ACN were added to the
Table 1
Physicochemical information of ABC, EFV, 3 TC and NFV.
Analyte ABC EFV 3 TC NFV
Chemical structure
Chemical formula C14H18N6O C14H9ClF3NO2 C8H11N3O3S C32H45N3O4S
MW (g moL1) 286.3 315.7 229.2 567.8
pKa 5.0 10.2 4.3 6.0 and 11.1
Solubility Solubility in H2O 1.2 g L1,
Soluble in methanol
Solubility in H2O 9.2 mg L1,
Soluble in methanol
Soluble in H2O,
Slightly soluble in methanol
Practically Insoluble in H2O,
Soluble in methanol
MW: Molecular weight.
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cipitate proteins and separate them. A 150 mL aliquot of the su-
pernatant was transferred to 2 mL vial and further diluted with
400 mL DW. A30 mL aliquot of the so prepared solution was injected
and analyzed into the UFLC-MS/MS.3. Results and discussion
As it is well known, CPE efﬁciency is conditioned by physico-
chemical variables as well as the matrix nature of the sample and
analytes [14,18]. Therefore, it is of interest to study the effect of the
experimental physicochemical variables on the analytical response
of the ARV and optimize it towards achieving high sensitivity and
selectivity of the methodology.
Developing analytical method using synthetic solution and
further application on real samples generally requires severe ad-
justments. This could lead to a new method different from the
former one. The use of real matrix all along the process is a
convenient choice for characterizing, studying and optimizing the
analytical methodology that is been developed. In this sense, not
only the signal enhancing due to the improvement of the extraction
efﬁciency resulted signiﬁcant, but also the matrix load minimiza-
tion, which led to a satisfactory chromatographic analysis. These
aspects werewhat ﬁnally determined the sensitivity and selectivity
of the resulting analytical methodology. Thus, those particular
factors of a real matrix, as well as all experimental variables that
condition the analytical responses of the ARV were evaluated,
including extraction pH, surfactant concentration, extraction time
and temperature, salting out effect and the use of modiﬁers,
including ACN, MeOH and acid, respectively. These studies were
carried out by modifying one variable at the time keeping constant
the remaining ones. A 500 mL aliquot of plasma, originally free of
ARV, was spiked with antiretroviral standard-mix (750 ng mL1
3 TC and ABC, 300 ngmL1 NFV and 150 ngmL1 EFV in H2O:MeOH
75:25 v/v) and 50 mL of Nelﬁnavir-d3 (Internal Standard,
2200 ng mL1) for carrying out the assays, which were done by
triplicate. The chromatographic peak area was used to evaluate the
impact of modiﬁed experimental conditions on the analytical
response.
From Section 3.2e3.5 are presented the results and discussion of
the relevant variables of this work. The remaining variables
mentioned above, did not show signiﬁcant effect on the analytical
response of the studied ARV.3.1. UFLC-MS/MS conditions
In the present work, the MS optimization was carried out using
direct infusion of standard solutions of each ARV into de ESI source
of the mass spectrometer at 20 mL min1 using a built-in syringe
pump. Base ion of each ARV was selected from full scan mode
recorded within the range 50e600 m/z. In all cases [MþH]þ mode
were selected. Declustering Potential (DP), Entrance Potential (EP)
and Collision Cell Entrance Potential (CEP) voltages were selected
according to the sensitivity of precursor base ions, whereas Colli-
sion energy (CE) and Collision Cell Exit Potential (CXP) were chosen
to give the maximum intensity of the obtained fragment base ion.
The remaining operative conditions were as follows: 250 ms dwell
time, 5500 V ion spray voltage, 20 psi nebulizer gas (GS1:N2), 20 psi
curtain gas, 7 psi collision gas (N2), 20 psi drying gas (GS2:N2),
500 C drying gas temperature and 100 C source temperature. The
mass spectrometer was used in the multiple reaction monitoring
(MRM) mode and the m/z transition for quantiﬁcation collected in
positive mode were 287.1/ 191.2, 316.0/ 168.2, 230.0/ 112.1,
568.4/ 330.1 and 571.4/ 333.1 for ABC, EFV, 3 TC, NFV and NFV-
d3, respectively.
The chromatographic separation was carried out using a mobile
phase of two components: A and B. A: 10 mMNH4Ac:ACN (70:30 v/
v) and B: 100% ACN. The ﬂow rate was set at 0.25 mL min1 and the
column temperature was kept at 40 C along the run. The injection
volume was 30 mL and the run time was 4 min. The retention time
for the target analytes were 1.30, 1.34, 1.61 and 2.06 min for ABC,
3 TC, NFV and EFV, respectively. Representative chromatograms of a
standard mixture of the analytes are illustrated in Fig. 1.
3.2. Surfactant concentration
Triton X-114 is one of the nonionic surfactant extensively used
for CPE [24]. It has been successfully applied for extracting a wide
range of analytes from biological [15,19] and environmental sam-
ples, including estrogens, vitamin A, vitamin E [16], kinds of pro-
teins, as well as metal ions [20,21]. Additional advantages include
commercial availability with high purity, low toxicity and low cost,
high density of the resulting surfactant reach phase facilitating the
phase separation by centrifugation, and relatively low coacervating
temperature [22].
Reports indicate that the amount of Triton X-114 not only
affected the extraction efﬁciency but also the resulting surfactant-
rich phase volume after phases separation [15]. The smaller the
Fig. 1. Chromatograms of plasma sample spiked with 1.7 mg mL1, 1.2 mg mL1, 0.8 mg mL1and 1.9 mg mL1 of ABC, EFV, 3 TC and NFV respectively.
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surfactant-rich phase volume leading to higher sensitivity of the
methodology. However, it is well known that a small surfactant-
rich phase volume (<20 mL) leads to operative difﬁculties to efﬁ-
ciently separate it from the supernatant, which affect on the ac-
curacy and reproducibility of the methodology [25].
Considering those aspects, four Triton X-114 concentrations
were assayed: 2.5%, 5.0%, 7.5% and 10.0%w/v. Higher concentrations
of surfactant were no assayed since it could affect the spectrometer
ion source performance, mainly by clog, which lead to signal loss.
The remaining steps were carried out as described in section 2.4.
Considering that different surfactant concentration would lead to
different surfactant reach phase volumes, it was referred to the
same ﬁnal volume (ca. 200 mL) with DW for all surfactant concen-
trations assayed in order to achieve comparable results. From Fig. 2,
it can be observe that the analytical response of ABC and 3 TC0
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Fig. 2. Extraction effect of target ARV as a function of Triton X-114 concentration.
Experimental conditions as described in Section 3.2.increased as the surfactant concentration increases. For EFV, the
highest analytical response was achieved for the smaller surfactant
concentration assayed falling to ca. 30% at 10% w/v Triton X-114.
NFV reported its highest relative response at 5% w/v Triton X-114
falling to ca. 75% at 10% w/v Triton X-114.
These results could be attributed to the analytes phys-
icalechemical properties inﬂuencing the extraction efﬁciency of the
CPE technique, and thus the analytical responses [26]. At the
working pH 3 TC and ABC were in their molecular form, while EFV
and NFV were in their ionic forms. They show different water sol-
ubility behavior (Table 1) coherent with their analytical responses. In
this sense, it is expected to obtain the lowest responses for 3 TC and
ABC since they are the most polar analytes and the surfactant is no-
ionic, limiting thus the afﬁnity between them and the micelles. The
performance of EFV could be attributed to the fact that at the lowest
surfactant concentration assayed, the extraction efﬁciency was the
maximum. Higher concentration led to higher surfactant reach
phase volume; therefore, concentration of the extracted analytes
was lower due to a dilution effect. In this sense, NFV reported the
highest analytical response at intermediate concentration, falling for
dilution into the resulting coacervate phase when higher surfactant
was used. The most polar analytes contain higher number of polar
atoms into their structure. This leads to higher molecular effective
radio due to the solvatation, reducing their interactionwithmicelles.
Therefore, 3 TC and ABC require higher surfactant concentration to
achieve a successful extraction and analytical response.
Based on these experiment results, 5% (w/v) Triton X-114 was
adopted as working condition considering it as the best compro-
mise concentration that lead to successful analytical response for
the studied ARV. This fact is relevant for the development of an
analytical methodology for a multi-component analysis.
3.3. Effect of pH
To the knowledge of the authors, CPE was not previously applied
for ARV extraction in any matrix; therefore there was no evidence
G.A. Hunzicker et al. / Analytical Chemistry Research 6 (2015) 1e8 5of which could be the pH effect on analytical signal for this meth-
odology. Analytical responses would be conditioned by CPE and
instrumental efﬁciency. CPE is strongly conditioned by physico-
chemical properties of the analytes, sample matrix, as well as CPE
particularities (surfactant type and concentration, matrix modi-
ﬁers, etc). On the other hand, instrumental efﬁciency is also
conditioned by sample matrix characteristic and analytes physi-
cochemical properties, additionally to the particularities of the
detection system. It is well know that plasma matrix contains dis-
solved proteins (6e8%) (i.e. albumins, globulins, and ﬁbrinogen),
glucose, clotting factors, electrolytes (Naþ, Ca2þ, Mg2þ, HCO3, Cl,
etc.), hormones and carbon dioxide [27,28] which could affect the
extraction efﬁciency of the CPE technique [29]. Considering that the
studied ARV are ionizable species according to their pKa (Table 1), it
was expected that extraction pH could affect their analytical re-
sponses as follows: the extraction pH may condition the ionizable
equilibrium of the ARV, and thus it molecular form, which affect
their afﬁnity for micelles, and consequently their extraction efﬁ-
ciency. On the other hand, it is important to highlight that due to
the nonionic character of the surfactant, it is not expected to see a
pH effect on micelles [16,17]. Considering this information, the ef-
fect of pH on the analytical response of ARV was analyzed. As
shown in Fig. 3, at pH 2.5 the lowest relative responses were ob-
tained for all ARV (<50%). At this pH the analytes were in the mo-
lecular form, thus it was expected to have the highest afﬁnity for
nonionic micelles.
On the other hand, it was observed an inefﬁcient phase sepa-
ration evidenced by on small volume of the surfactant rich phase
(<50 mL), which affected the extraction efﬁciency and consequently
their analytical response.
At pH 5 the resulting coacervate phase volume was ca. 450 mL
and showed turbid, which clear up after a protein precipitation
step. At this pH, 3 TC and ABC prevailed in ionic form, while NFV
and EFV prevailed in their nonionic form according to their pKa. On
this basis, it was expected to see lower relative responses for the
ionic analytes since they would have lower afﬁnity for the nonionic
micelle, and therefore, lower extraction efﬁciency for these ARV.
However, the analytical response of ARV reached their highest
values at pH 5 (>95%), except for NFV (ca. 70%), and remained
invariant only for EFV at higher pH values. These results could be
due to the tradeoff between the effect of afﬁnity of the analyte by
the micelles and their efﬁciency in forming, resulting in an
improvement of the analytical signal. NFV analytical responses
reached the highest values (>95%) at pH 9 and remained invariant
at pH 11.5. The analytical responses of 3 TC and ABC decreased from0
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Fig. 3. Effect of pH on the analytical response of target ARV. The concentration of each
antiretroviral was 0.5 mg mL1. Experimental conditions as described in Section 3.3.pH 7 and pH 9, respectively. Phases separation was efﬁcient from
pH 7 ahead, obtaining a coacervate-phase volume of ca. 350 mL.
Coacervate phase showed the highest dehydration and the smaller
volume (ca. 300 mL) at pH of 11.5; resulting in a better phases
separation performance and reducing of the loss of coacervate
phase when the supernatant was discharged. The decrease in the
analytical signal of ABC and 3 TC at pH 11.5 could be due to a signal
suppression effect in the mass spectrometer because of a high
matrix load in the solvent front. Considering the short retention
time of ABC and 3 TC (1.30 and 1.34 min1, respectively) it was
expected that their analytical signal were more affected by this
phenomenon than for NFV and EFV, whose retention time were
higher (1.61 and 2.06 min1, respectively).
Based on these results, pH 7.5 was adopted as working condition
considering it as the best compromise pH that lead to successful
analytical response for the studied ARV. Considering that human
plasma pH is 7.4 [27], the extraction pH was not adjusted for CPE of
ARV from plasma. This fact is relevant for the development of an
analytical methodology for a multi-component analysis since it
simplify the procedure.
3.4. Optimization of extraction temperature and time
Reported cloud point temperatures for TritonX-114 are within
the range of 15e20 C [19]. It refers to the temperature at which the
surfactant coacervation results notorious in the extraction system,
because of its turbid aspect. As it is well known, extraction tem-
peratures above the cloud point, and/or the extended extraction
time (>2 min), diminishes the water content of the resulting sur-
factant reach phase, and thus, its ﬁnal volume [25]. This argument
is based on the fact that as the extraction temperature increases,
the hydrogen bonds are disrupted leading, thus, to dehydration of
micelles [25]. On the other hand, it is important to take into account
that the use of excessive high extraction temperature can reduce
the CPE efﬁciency, because of the thermal stability of surfactant
aggregates [30] as well as the analytes lability. Therefore, it was of
interest to study the effect of the extraction temperature on the
extraction systemperformance, as well as on the analytes analytical
response along with the extraction time within the range 45e75 C
and 10e30 min, respectively. The extraction temperature assays
were carried out considering a 20 min extraction time; while the
time assays, were carried out at the optimum temperature resulting
from the former. As the temperature increased from 45 to 65 C a
better surfactant-rich phase separation as well as an increased
response of the analytes was observed. The results showed no
signiﬁcant change neither on the CPE performance nor on the
analytical response of the studied ARV at extraction temperatures
above 65 C. Therefore, 65 Cwere chosen for further assays. For the
extraction time, it was observed that by increasing it, the relative
response is subsequently increased, reaching the maximum
analytical responses of the studied ARV at 20 min; after which, and
remained invariant. Thus, in the following experiments, an
extraction time of 20 min was selected for the extraction.
3.5. Analytical performance and method validation
The proposed analytical multi-component method was evalu-
ated in terms of linearity, recovery, accuracy and precision intra-
and inter-day, selectivity and sensitivity. Blank plasmawas assessed
in six different batches of plasma samples by analyzing blanks and
spiked samples at LOQ levels. The calibration curves were made
under optimized conditions following the proposed methodology,
which was described above. Blank plasma were spiked with ARV
standards achieving different concentration levels [31,32]. No sig-
niﬁcant chromatographic signals of endogenous ARV were
Table 2
Analytical ﬁgures of merit of CPE-UFLC-ESI-MS/MS for analysis of ARV in human plasma.
Analyte ABC EFV 3 TC NFV
LOQ (CV%) 43 (6.9) 125 (19.0) 81 (0.1) 49 (5.3)
Linear Range ng mL1 43e6816 125e4992 81e3248 49e7904
Correlation coefﬁcient r ¼ 0.99 r ¼ 0.99 r ¼ 0.99 r ¼ 0.99
Concentration
(ng mL1)
Concentration
(ng mL1)
Concentration
(ng mL1)
Concentration
(ng mL1)
Added Found RE (%) Added Found RE (%) Added Found RE (%) Added Found RE (%)
Accuracy intra-day 85 75 12 125 104 17 81 65 20 99 91 8
1704 1808 6 1248 1279 3 812 819 1 1976 1986 1
3408 3675 8 2496 2715 9 1624 1689 4 3952 4230 7
Accuracy inter-day 85 72 15 125 111 11 81 70 13 99 93 6
1704 1669 2 1248 1215 3 812 898 11 1976 2034 3
3408 3447 1 2496 2559 3 1624 1821 12 3952 4295 9
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retention times.
The analytical ﬁgures of merits were summarized in Table 2. The
LOQ was deﬁned as the lowest concentration in the standard curve
that can be measured with acceptable accuracy and precision ac-
cording to international requirements [31,32]. In this sense, the
criteria for evaluating the accuracy were as follows: relative error
(RE) value should be within 15% of the spiked value except at LOQ,
where it should not deviate by more than 20%. The regression
equations with a weighting factor of 1/x (where x ¼ concentration)
were judged to produce the best ﬁt for the concentration-detector
ratio response for all ARV in plasma [22,23]. The calibration curves
showed a satisfactory linearity within the concentration range:
43e6816 ng mL1, 125e4992 ng mL1, 81e3248 ng mL1 and
49e7904 ng mL1 for ABC, AFV, 3 TC and NFV, respectively. These
concentrations were chosen based on the expected pharmacoki-
netic studies of drugs containing these active values. Calibration
data was ﬁtted by using a 1/x curve resulting coefﬁcients of cor-
relation (r2) > 0.99 for all analytes. The intra- and inter-day preci-
sion assay was evaluated over three replicates at three
concentration levels. The precision was evaluated over the sample
preparation step of the proposed methodology. The precision was
determined at each concentration level, and did not exceed 15% of
the percent relative standard deviation (%RSD) except for the LOQ,
which it did not exceed 20% of the RSD [31,32]. The resulting RSDs
values in the LOQ level ranged from 0.10 to 19%, and 1.0e15% for the
remaining concentration level. The stability of ARV in human
plasma after three freezeethaw cycles, short-term room stability
(6 h), post processing stability (12 h remain at the auto-sampler
temperature) and long-term stability (119 days at 20 C) were
evaluated. The ARV analyzed were considered to be stable in hu-
manplasma or extracts when accuracywaswithin±15% (Table 3). ATable 3
Stability of the ARV in plasma samples at different conditions.
Stability Room temperature (6.0 h) Autosampler sam
Found RE % %RSD Found RE %
ABC Low (72 ng mL1) 82 112.9 8.0 82 113
Middle (3367 ng mL1) 3210 95.3 2.3 3684 109
High (6266 ng mL1) 6046 96.5 2.4 6264 100
EFV Low (226 ng mL1) 237 104.8 4.8 239 105
Middle (2259 ng mL1) 2322 102.8 2.0 2431 107
High (4518 ng mL1) 4807 106.4 3.5 4545 100
3 TC Low (78 ng mL1) 79 100.8 9.2 87 111
Middle (1756 ng mL1) 1715 97.7 5.1 1777 101
High (3267 ng mL1) 3053 93.4 2.7 3211 98
NFV Low (102 ng mL1) 104 101.6 4.2 110 107
Middle (3250 ng mL1) 3402 104.7 3.4 3400 104
High (6500 ng mL1) 6324 97.3 5.6 6740 103typical chromatogram of spiked plasma sample is shown in Fig. 1.
The proposed methodology meets standards required by interna-
tional guidelines for pharmacokinetic studies of drugs, as well as
for therapeutic monitoring of HIV patients. CPE technique resulted
efﬁcient, quick and easy to carry out the sample preparation for
ARV analysis in plasma by 4 min run UFLC-MS/MS.
4. Comparison of proposed CPE-UFLC-MS/MS with previously
reported analytical methodologies
The proposed methodology, CPE-UFLC-MS/MS, developed for
analyzing multiple ARV in plasma samples, presents several char-
acteristics that makes it suitable for routine analysis. Table 4
summarizes analytical methodologies for analyzing ARV in
plasma samples. The ﬁgures of merit satisfy the requirements of
international guidelines so the analytical methodology is suitable
for bioequivalence studies. The resulting analytical ﬁgures of merits
(linear range, %RSD, recovery (%), and running time) are within the
values reported for other methodologies. It can be successfully
applied for analyzing four main ARV (ABC, EFV, 3 TC, and NFV) used
for HIV treatments in a reasonable running time (4 min). The
proposed technique, CPE, is suitable for batch preparations of
samples feasible to be carried out in 25 minwith simple equipment
available in most of the laboratories. It does not include a solvent
evaporation step, neither requires toxic solvents, regularly used for
traditional techniques, like LLE and SPE.
5. Conclusion
This work presents a valuable contribution to analytical chem-
istry ﬁeld as well as those related disciplines including pharma-
cology, biochemistry and medicine, principally. A new applicationple (12 h) Freeze and thaw (cycle 3) Long-term (119 days)
%RSD Found RE % %RSD Found RE % %RSD
.6 5.2 84 115.3 8.0 81 111.8 9.6
.4 4.9 3851 114.4 3.0 3659 108.7 3.6
.0 2.7 6545 104.5 2.3 6349 101.3 5.9
.6 0.7 219 97.1 0.8 247 109.4 1.5
.6 1.9 2345 103.8 3.7 2306 102.1 2.3
.6 0.4 4839 107.1 4.8 4694 103.9 2.8
.6 4.3 83 106.0 4.8 80 102.8 5.8
.2 5.0 1726 98.3 5.8 1640 93.4 7.0
.3 1.5 3055 93.5 3.0 2963 90.7 7.5
.7 4.3 114 111.4 4.5 109 107.3 6.4
.6 1.0 3337 102.7 3.1 3417 105.1 2.2
.7 3.6 6452 99.3 4.5 6216 95.6 6.7
Table 4
Analytical methodologies for analyzing ARV in plasma samples.
Instrumental
technique
Analyte Extraction
technique
Sample size
(mL)
Linear range
(ng mL1)
LOD
(ng mL1)
Reproducibiltya
(RSD %)
Recoveries
(%)
Running time
(min)
HPLC-UV [2] ABC LLE 1000 200 e 10,000 n.a. <8.0 66 n.a.
NFV 51
EFV 54
LC-MS/MS [5] ABC LLE 100 30 e 9318 n.a. <10.8 87 2
HPLC-UV [11] ABC SPE 800 10 e 10000 n.a. <7.6 >97 40
3 TC <9.1 >90
LC-MS/MS [33] EFV SPE 100 20 e 2000 n.a. <8.4 54 4
LC-MS/MS [34] 3 TC SPE 100 1 e3000 n.a. <8.3 94 9
LC-MS/MS [35] ABC SPE 200 100 e 7000 1 <7.6 59 2
3 TC 80 e 5000 1 <9.1 105
UFLC-MS/MSb ABC CPE 500 43 e 6816 31 <9.2 90 4
EFV 125 e 4992 77 <13.7 105
3 TC 81 e 3248 57 <14.7 82
NFV 49 e 7904 21 <6.4 98
n.a.: not available.
a The values of intra-and inter-day precision were compared.
b Proposed methodology.
G.A. Hunzicker et al. / Analytical Chemistry Research 6 (2015) 1e8 7of the CPE for the analysis of ARV in human plasma by UFLC-MS/MS
was proposed for direct application in real studies. The CPE-UFLC-
MS/MS was developed on real matrices, which allowed a compre-
hensive characterization and optimization of the procedure with a
feasible validation according to international standards. The pro-
posed analytical methodology was developed and applied for
analyzing of ABC, EFV, 3 TC and NFV in human plasma. Under
optimized working conditions the proposed analytical methodol-
ogy meets standards requirements of international guidelines,
which makes it suitable for pharmacokinetic studies of four ARV, as
well as for therapeutic monitoring of HIV patients. Additionally to
its analytical performance, it is important to point out that the
proposed sample preparation technique has an environmentally
friendly character that makes it suitable for current green chem-
istry trends.
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